Theriva Biologics (Theriva Biologics) Cash And Cash Equivalents : $23.18 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Cash And Cash Equivalents?

Theriva Biologics's quarterly cash and cash equivalents declined from Jun. 2023 ($34.25 Mil) to Sep. 2023 ($31.16 Mil) but then stayed the same from Sep. 2023 ($31.16 Mil) to Dec. 2023 ($23.18 Mil).

Theriva Biologics's annual cash and cash equivalents declined from Dec. 2021 ($67.33 Mil) to Dec. 2022 ($41.79 Mil) and declined from Dec. 2022 ($41.79 Mil) to Dec. 2023 ($23.18 Mil).

Theriva Biologics Cash And Cash Equivalents Historical Data

The historical data trend for Theriva Biologics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Cash And Cash Equivalents Chart

Theriva Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

15.05

6.23

67.33

41.79

23.18

Theriva Biologics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															41.79	36.08	34.25	31.16	23.18

Theriva Biologics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Theriva Biologics (AMEX:TOVX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Theriva Biologics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Theriva Biologics (Theriva Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SFY:Germany

Address

9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850

Website

https://www.therivabio.com

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Executives

Steven A Shallcross	director, officer: CEO and CFO	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro	officer: Chief Operating Officer	9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan	director
Scott Tarriff	director	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman	officer: CHIEF MEDICAL OFFICER	9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp	10 percent owner	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne	officer: CHIEF FINANCIAL OFFICER	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks	director	C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr	director, officer: CEO & President	C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome	officer: Chief Scientific Officer	3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman	director
Wayne George Holman	10 percent owner	430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022